Objective: To study association between relevant cardiovascular pharmacotherapy and incident congestive heart failure (CHF) in patients with atrial fibrillation treated in primary health care.
INTRODUCTION
A trial fibrillation is the most common form of arrhythmia in the global population. In Sweden, the prevalence of a registered diagnosis of atrial fibrillation has been estimated at 2% [1] and to be almost 3% in individuals aged above 20 years [1, 2] .
Congestive heart failure (CHF) and atrial fibrillation are interrelated conditions [3, 4] ; CHF is three times more common among patients with atrial fibrillation than in patients without atrial fibrillation [5] . Among the elderly population, CHF is the most common cardiovascular (CVD) condition [6] and, according to a recent American study, incident CHF in patients with atrial fibrillation has not declined over time [7] . Furthermore, CHF is associated with increased mortality in patients with atrial fibrillation [5] , on a par with stroke [8] .
We have also found hypertension to be associated with a lower risk of incident CHF among atrial fibrillation patients [9] , which is why it is of great interest to study the effect of different classes of antihypertensive drugs on CHF development in patients with atrial fibrillation.
The most effective drugs associated with preventing incident CHF among patients with hypertension are, according to a systematic review, diuretic drugs. Thiazides are the most frequently used diuretic drugs, followed by angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) [10] . However, less is known about the preventive effect of these drugs on incident CHF in patients with atrial fibrillation. We have found in a previous study that prescribed thiazides, calcium channel blockers, and statins were associated with a lower mortality rate among patients with atrial fibrillation [11] , and that patients with atrial fibrillation and concomitant heart failure have a lower mortality rate when prescribed calcium channel blockers and statins [12] .
Atrial fibrillation is more common among men [1] , and men develop atrial fibrillation, on average, 5 years earlier than women [13] . By contrast, women with atrial fibrillation have been shown to have a higher risk of stroke and of mortality than men with atrial fibrillation [14] .
We hypothesized that there may be differences in the associated risk of incident CHF in those treated with different cardiovascular drugs in patients with atrial fibrillation. Accordingly, the aim was to study relevant cardiovascular pharmacotherapies and the associated risk of incident CHF in patients with atrial fibrillation. We also aimed to explore potential differences among men and women as well as in those over and under 75 years of age.
METHODS

Design
This study used individual-level patient data from 75 primary health care centers (PHCCs), 48 of which were located in Stockholm County. Individuals that attended any of the participating PHCCs between 2001 and 2007 were included in the study. We used Extractor software (http:// www.slso.sll.se/SLPOtemplates/SLPOPage1____10400.aspx; accessed 19 September 2010) to extract individual electronic patient records (EPRs). National identification numbers were replaced with new unique serial numbers to ensure anonymity. The files were linked to a database constructed using the Total Population Register, the Inpatient Register, and the Swedish Cause of Death Register, which contains individual-level data on age, sex, education, and hospital admissions for all residents registered in Sweden. Thus, a new research database containing clinical data and information on socioeconomic status on the individuals (n ¼ 1 098 420) registered at the 75 PHCCs was created. Data from the Cause of Death Register was used for the follow-up.
Ethical approvals were obtained from regional boards at Karolinska Institutet and the University of Lund.
Study population
The study included patients who had been diagnosed with atrial fibrillation as identified by the presence of the ICD-10 code (10th version of the WHO's International Classification of Diseases) for atrial fibrillation (I48) in patients' medical records. Patients with a first diagnosis of CHF during the period were identified, and patients with a first hospital episode of CHF before, or in the same year, as the first atrial fibrillation diagnosis were excluded (n ¼ 2859), as well as patients with a first CHF after atrial fibrillation diagnosis but before 2006 (n ¼ 552), or deceased before 2006 (a further 211 patients excluded). In addition, as we also included patients with a new CHF diagnosis in primary care, and a total of 124 patients were excluded with an atrial fibrillation diagnosis the same year or after CHF diagnosis, and 562 with a primary care diagnosis of CHF before 2006. In total, 4308 patients were excluded from the analyses. Included in the study were the following: 7975 individuals (4510 men and 3465 women), 1552 (803 men and 749 women) with, and 6423 without a recorded episode of CHF, aged 45 years or older at the time of atrial fibrillation diagnosis, and who visited any of the 75 participating PHCCs from 1 January, 2001, until 31 December 2007, and with data on neighbourhood socioeconomic status.
Pharmacotherapies
Data on dispensed prescriptions of drugs, classified according to the Anatomic Therapeutic Chemical (ATC) Classification, were collected from the Swedish Prescribed Drug Register (National Board of Health and Welfare) from 1 July 2005, that is, when the register became operational, and until 31 December 2010 [15, 16] . Substances were recorded, meaning that medical drugs could be single-substance drugs, or combined medical drugs with the substances recorded separately, for example, a reninÀangiotensin system (RAS)-blocking agent combined with a thiazide, which would thus be recorded into two separate groups. Digitalis agents (C01AA) were recorded. Diuretic drugs (C03) were recorded as thiazides or related agents, also registered when in combination with other drugs (C03A, C03B, C03E, C09B, and C09DA), loop diuretics (C03C), or aldosterone antagonists (C03DA). Furthermore, the following cardiovascular agents were recorded: beta blockers with beta-1-selective agents (C07AB and C07FB) and nonselective agents (C07AA and C07AG), calcium channel blockers with heart-active agents (C08DA) and vesselactive agents (C08CA and C08DB), and RAS-blocking agents with ACE inhibitors (C09AA and C09BA), and angiotensin receptor blocking (ARB) agents (C09CA, C09DA, and C09DB). In addition, sotalol was recorded separately (C07AA07). Statins (C10AA) were also recorded.
Outcome variable
Time to first CHF episode during the study period (from registration of first atrial fibrillation diagnosis during [2001] [2002] [2003] [2004] [2005] [2006] [2007] ; until end of follow-up, 31 December 2010), was defined as having a hospital or primary care diagnosis of CHF ICD-10 code (I50 or I110).
Demographic and socioeconomic variables
Sex: men and women.
Individuals were divided into the following age groups 45-54, 55-64, 65-74, 75-84, and at least 85 years. Individuals younger than 45 years were excluded as they rarely develop atrial fibrillation and CHF.
Educational level was categorized as 9 years or less (partial or complete compulsory schooling), 10-12 years (partial or complete secondary schooling), and greater than 12 years (college and/or university studies). Information on education was missing for 409 individuals.
Marital status was classified as married, unmarried, divorced, or widowed. Information on marital status was missing for 14 subjects.
The neighbourhood socioeconomic status (SES) areas were categorized into three groups according to the neighbourhood index: more than one SD below the mean (high SES or low deprivation level), more than one SD above the mean (low SES or high deprivation level), and within one SD of the mean (middle SES or deprivation level).
Comorbidities
We identified the following cardiovascular comorbidities from the EPRs among individuals in the study population: hypertension (I10-15), coronary heart disease (CHD; I20-25), nonrheumatic valvular diseases (I34-38), cardiomyopathy (I42), and cerebrovascular diseases (CVDs; I60-69). No diagnosis of rheumatic valvular diseases (I05-08) was recorded. In addition, we also included obesity (E65ÀE68), diabetes mellitus (E10-14), COPD (J40ÀJ47), obstructive sleep apnoea syndrome (G47), depression (F32ÀF34, F38-F39), and anxiety disorders (F40-41). We also had access to diagnoses from hospital records and the Cause of Death Register for data regarding myocardial infarction (I21), ischemic stroke (I63), and haemorrhagic stroke (I60-62). Thus, diagnoses of CHD and CVDs included data from primary care and from hospital records.
Statistical analyses
We used Student's t-test to study differences in age between subjects, with or without incident CHF diagnosis during follow-up, and chi-square test was used to study differences in age distribution. Differences in distributions of sociodemographic data, comorbidity, and prescribed drugs were otherwise performed by using age-adjusted logistic regression or analysis of co-variance (ANCOVA).
Cox regression with hazard ratios and 95% confidence interval (95% CI), using time-to-first diagnosis of CHF as the outcome was used. The following were studied in the analyses: digitalis, thiazides, loop diuretics, aldosterone antagonists, beta blockers, calcium channel blockers, RASblocking agents, and statins, with subdivision for beta blockers into beta-1-selective or unselective, calcium channel blockers into heart or vessel active, and RAS blockers into ACE inhibitors and ARB. In the full model, we adjusted for sex, age, socioeconomic factors, comorbidities, and drug classes. The regression models were also tested for possible interactions between (with confirmed interactions between age and marital status, and age and neighbourhood status).
We also stratified Cox regression into subgroups, that is, men and women, subjects aged less than 75 and at least 75 years of age, and with or without concomitant cardiovascular diseases, that is, CHD, valvular heart disease, cardiomyopathy, and cerebrovascular diseases. We used 75 years as the cut-off for age as this is the cut-off for high age in CHA 2 DS 2 -VASc.
Furthermore, owing to the results for the nonselective beta-blocking agents, we decided to perform a separate analysis for sotalol, and also an analysis of RAS blockers and thiazides in combination or not.
A P value for two-sided tests of less than 0.01 was considered statistically significant because of the multiple comparisons between men and women. A two-sided P value of less than 0.05 was considered statistically significant for variables in the Cox regression. All analyses were performed in STATA 15.1. http://links.lww.com/HJH/A953. Overall, men were significantly younger and had a higher educational level than women, whereas significantly more women were widowed than men. Hypertension was more common among women, and cardiomyopathy was more common among men. The mean follow-up time was 5.70 years (SD 2.34 years), and hazard ratios were calculated based on 45 465 person-years at risk; 26 044 among men and 19 421 among women. Table 2 shows rates of dispensed pharmacological drugs in subjects with or without incident CHF diagnosis during follow-up, with age-adjusted P-values shown, and P-values less than 0.01 regarded as significant. Regarding differences by sex, men with new CHF constituted more digitalis and loop-diuretic prescriptions, and less thiazides, beta-1-selective beta blockers, and vessel selective calcium receptor blockers; women with a new CHF diagnosis constituted more digitalis, loop-diuretic prescriptions, and aldosterone antagonists dispenses, and less thiazides, vessel selective calcium receptor blockers, and statins (Supplementary  Table 2 , http://links.lww.com/HJH/A953).
RESULTS
Cox regression models are shown in Table 3 for all subjects with incident CHF as outcome, also characterized into subgroups, that is, for men and women, low or high age (<75 years and !75 years), and with or without cardiovascular comorbidities (CHD, valvular heart disease, cardiomyopathy, and cerebrovascular diseases). Differences by groups were tested by interactions, finding significant differences by low or high age-group for loop diuretics, and for beta-1-selective beta blockers, and by inclusion of cardiovascular comorbidity or not for loop diuretics and vessel-active calcium channel blockers. Dispensing of thiazides and vessel active calcium blockers were associated with a lower risk of incident CHF in general as well as in all studied subgroups, and loop diuretics were associated with a higher risk in general and in all subgroups. Nonselective beta blockers were associated with a lower risk in general, and in patients without cardiovascular comorbidities, and aldosterone antagonists with a higher risk in general, among women and among patients aged at least 75 years. Beta-1-selective beta blockers were associated with a lower risk only among patients aged less than 75 years, heart-active calcium channel blockers with a lower risk in patients with cardiovascular comorbidities, and statins with a lower risk in women, patients aged less than 75 years, and in patients with cardiovascular comorbidities.
In a separate analysis, we also performed analyses for sotalol, that is, the mostly used of the nonselective beta blockers (1140 out of 1407, that is, 81.0% out of all nonselective beta blockers; 675 among men and 465 among women). In the full model using Cox regression the hazard ratio was 0.81 (95% CI 0.69-0.97); in men 0.81 (95% CI 0.64-1.02), and women 0.80 (95% CI 0.62-1.04); in patients aged less than 75 years hazard ratio 0.81 (95% CI 0.63-1.03), and aged at least 75 years 0.78 (95% CI 0.61-1.00, P ¼ 0.048); and finally in patients with cardiovascular diseases 0.72 (95% CI 0.55-0.94), and in patients without cardiovascular diseases 0.88 (95% CI 0.70-1.11). No significant interactions when testing for sub-groups were found.
We also tested the combination of thiazides and RAS blockers, with the following hazard ratios (with 95% CI) vs. use of neither thiazides nor RAS blockers (n ¼ 3242; 40.7%): RAS blockers (n ¼ 2279; 28.6%) 1.13 (0.99-1.29), thiazides (n ¼ 611; 7.7%) 0.72 (0.58-0.90), and RAS blockers and thiazides combined (n ¼ 1843; 23.1%) 0.77 (0.65-0.90).
DISCUSSION
The main finding of this study was that thiazides and vessel selective calcium receptor blockers were associated with a lower risk of incident CHF, among both men and women, as well as among younger and elderly individuals. Nonselective beta blockers, more specifically sotalol, were associated with a lower risk of incident CHF risk among patients under 75 years of age. On the other hand, loop-diuretics were associated with a higher risk of incident CHF among men and women.
One might have expected a lower CHF associated with some of the other pharmacotherapies, especially RAS blockers [10] . However, the results in this observational study could be influenced by different factors, and competing risk factors could contribute to CHF especially among elderly individuals, and also confounding by indication [17] . Furthermore, differences may exist between patients with and without atrial fibrillation and the risk of CHF, which may explain why our results differ from other studies concerning the risk of CHF associated with cardiovascular drugs [10] . In addition, it is possible that certain drugs were prescribed because of concomitant diseases before the CHF occurred.
The effect of thiazides on incident CHF concurs with earlier findings [10] . However, in the review by Sciarretta, the effect was seen in all diuretics when used as antihypertensive therapy [10] , whereas we saw different results depending on the kind of diuretic used; with an excess risk found for the use of loop diuretics.
The negative effect associated with the use of loop diuretics is in line with an earlier reported finding with an associated increase in mortality among atrial fibrillation patients younger than 80 years of age who were using loop diuretics [11] . As these drugs are often prescribed to patients Hazard ratio (95% CI)
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Hazard ratio (95% CI) Models are adjusted for sex, age, sociodemographic status (educational level, marital status, and neighbourhood SES), drug treatment and comorbidity (myocardial infarction, valvular heart disease, cardiomyopathy, cerebrovascular diseases, hypertension, obesity, diabetes, COPD, obstructive sleep apnoea syndrome depression and anxiety); however, in patients with. Interaction terms are included (age and marital status, and age and neighbourhood SES). Hazard ratios and 95% CIs are shown. Statistically significant hazard ratios are highlighted in bold. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CIs, confidence intervals.
Drugs and heart failure in atrial fibrillation with CHF, the most likely explanation is that these patients did have prior symptoms associated with CHF, for example, leg edema, before they were diagnosed with CHF. Thus, our finding of an increased risk of CHF in patients who were using loop diuretics was likely confounded by indication, or reversed causation.
The associations between vessel-selective calcium channel blockers and a reduced risk of incident CHF are also of interest. Previous studies have shown conflicting results regarding calcium channel blockers in relation to heart failure; one review reported a reduced rate of CHF in individuals prescribed antihypertensive agents [18] , and another a positive effect by calcium channel blockers, although with a less positive effect than thiazides and RAS agents [10] . In contrast, another review reported an increased risk of incident CHF [19] . Calcium channel blockers may, however, be beneficial in patients with CHF with preserved ejection fraction (HFpEF) [20] . This type of CHF is regarded to be more common among elderly individuals, especially women, and also to be more common in primary care. The rate of dispensed calcium channel blockers was considerably lower than that of RAS blockers and of beta blockers.
Regarding beta blockers, nonselective beta blockers, especially sotalol, were associated with a lower CHF risk, which was seen among patients younger than 75 years of age. We found no statistically significant effect of beta-1-selective beta blockers, although point estimates indicated a lower risk. Beta-1-selective agents were dominant among beta blockers in our study, which is in contrast to the situation during the late 1990s [21] when sotalol was prescribed to 25% of atrial fibrillation patients in primary care, and sotalol accounted for 78% of prescribed nonselective beta blockers in the present atrial fibrillation cohort [22] , and 80% of the dispensed prescriptions in this specific study. Sotalol has a more specific anti-arrhythmic profile in maintaining sinus rhythm in contrast to the beta-1-selective agents and other beta blockers [22] , and this could possibly explain the positive effect we found. However, owing to adverse events, the use of sotalol for atrial fibrillation patients in primary care decreased during the early years of the 21st century [22] . Beta blockers have also been shown to be effective in preventing CHF in patients with hypertension [23] . However, it has been questioned if beta blockers are effective in patients with concomitant atrial fibrillation and CHF, and the effect on mortality has been neutral, in comparison with CHF patients with sinus rhythm where beta blockers are associated with reduced mortality [24] .
On the other hand, the lack of effect of RAS blockers, both ACE inhibitors and ARBs, is surprising, and we do not have a sufficient explanation for this unexpected finding. RAS blockers seem to prevent incident atrial fibrillation [25] , and are effective in preventing CHF in patients with hypertension [23] . In a previous study in patients with atrial fibrillation on the association between prescribed drugs and mortality, RAS blockers did neither increase nor decrease the mortality risk [11] . This finding could be an effect of confounding by indication, for example, patients with a higher cardiovascular risk, such as the presence of CHD as in the present study, or perhaps with signs of CHF without a definite diagnosis, might be prescribed RAS blockers more often than those without such signs.
There are several limitations of this study, which must be kept in mind whenever interpreting the results. As this is an observational study, the findings may have been subject to confounding by indication [17] . To account for this effect, we also analyzed data with concomitant cardiovascular diseases excluded. We used data from registers and electronic patient records. One question raised by the findings, especially on the results from loop diuretics, is that when a CHF diagnosis is set, it seems to be at a late rather than at an early stage. The study sample is a selected group, that is, patients with a diagnosis of atrial fibrillation registered in primary health care. In another study, it was found that 36% of all registered atrial fibrillation patients in Stockholm County were not registered with a diagnosis in primary health care [1] . However, we do not know the validity of registered diagnoses in primary health care (accounting for 9% of the total events of incident CHF), and there might be both overestimation and underestimation of diagnoses, in particular with CHF. For CHF diagnoses registered in hospital records, good validity has been shown [26] , and in a meta-analysis, the sensitivity of a CHF diagnosis from registers was found to be around 75% [27] . Clinical data were also highly complete [28] . We did not have access to doses of the retrieved drugs, which is especially of importance for diuretic drugs. Severity of CHF and CHD were not available to us from the patient records, even if it is probable that these patients from primary care had less severe CHF than patients from hospital care. In addition, patients in primary care probably more often have a CHF with preserved ejection fraction. As severity of CHF is an important factor for mortality, this is also a major limitation of the study. In addition, data on ejection fraction and criteria for diagnosis of CHF were not available. Moreover, atrial fibrillation could not be classified as paroxysmal, persistent, or permanent and heart rhythm could not be classified as sinus rhythm or fibrillation rhythm. In addition, we did not have access to renal function data. All these mentioned factors could have affected the results, and yielded discrepant findings.
A major strength of this study was that we were able to link clinical data from individual EPRs to data from national demographic and socioeconomic registers with less than 1% of information missing. We used the Swedish Prescribed Drug Register [15, 16] , in which dispensed prescriptions of drugs are registered, and thus showed a higher probability of being used compared with only prescription data. In addition, whereas many previous follow-up studies of atrial fibrillation have used hospital data, the current study used data from primary care, which may better reflect the risks associated with atrial fibrillation in society. Most patients with hypertension and diabetes are actually cared for in primary care in Sweden [29] . However, access to diagnoses of CHD and CVDs from hospital records is important, as these diagnoses are not always identified in primary care in Stockholm County, Sweden [30] . Moreover, randomized controlled trials often exclude individuals with comorbidities, such as patients with atrial fibrillation with concomitant diabetes and CHF. In the current study, we had the possibility to include these patients in the analyses, which means that the findings are more representative of the variety of patients encountered in clinical practice today.
In conclusion, our findings suggest that the risk of developing CHF may be reduced in atrial fibrillation patients in primary care by use of thiazides, and vesselactive calcium channel blockers in general and consistently in all studied subgroups. The use of these drugs in patients with atrial fibrillation is also supported by previous studies where they have been shown to be associated with a lower risk of mortality, also in patients with atrial fibrillation and concomitant CHF. Other drugs showed an effect in some specific subgroups, such as nonselective beta blockers, specifically sotalol, beta-1-selective beta blockers, heartactive calcium channel blockers and statins. However, we believe that the present observational study needs to be interpreted with caution, as confounding by indication may explain some of our results. More studies focusing on patients with atrial fibrillation treated in a primary care setting with data on severity of CHF, ejection fraction, and kidney function are needed to confirm our findings.
